Immunogenicity of 9-valent HPV Vaccine

Status Recruiting

Clinical Trial Summary

Human papillomavirus (HPV) causes the most prevalent sexually transmitted infections in the world. The nonavalent HPV vaccine (9vHPV) provides protection against 9 high-risk HPV serotypes, responsible for causing approximately 90% of cervical and other HPV-related anogenital cancers, as well as 90% of genital warts. The risk of cancer is substantially increased among immunocompromised patients. Although studies have demonstrated seroprotection among children and adolescents, boys and girls, with the 9vHPV vaccine, the immunogenicity of this vaccine has been poorly explored in immunocompromised children and adolescents (including transplant patients, and those infected with human immunodeficiency virus (HIV)). Several factors, including the immunological consequences of vertically acquired infection, immunosuppressive therapies and age, could lead to an increased risk of infection in children and adolescents who are immunocompromised. Lower immunogenicity in these populations. These children may have a poor response to vaccines and therefore require additional doses. Markers such as CD4/CD8 or torque teno virus (TTV) replication could be linked to immunogenicity and thus serve as predictors of efficacy for routine clinical practice.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05439083
Study type	Interventional
Source	Instituto de Investigación Hospital Universitario La Paz
Contact	Talia Saínz Costa
Phone	+ 34 91 727 74 43
Email	talia.sainz@salud.madrid.org
Status	Recruiting
Phase	Phase 4
Start date	March 7, 2023
Completion date	March 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04199078` - Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions.	N/A
Active, not recruiting	`NCT02135419` - Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions	Phase 3
Active, not recruiting	`NCT02258659` - Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer	Phase 2
Completed	`NCT02714114` - Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine (AB-SOP Study)	N/A
Completed	`NCT00303823` - Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia	Phase 2
Not yet recruiting	`NCT05510830` - Diagnostic Cervical Conization for Persistent Infection or Integration of HPV	N/A
Completed	`NCT04002154` - Clinical Trial to Explore the Papilocare Gel Efficacy to Repair the Cervico-vaginal Mucosa With Lesions Caused by HPV	N/A
Not yet recruiting	`NCT06123533` - Understanding Women's Values in Managing Human Papillomavirus (HPV)
Completed	`NCT04624568` - Papilocare®: Effects on Regression of Histologically Confirmed Cervical Intraepithelial Lesions 1 and Tolerance	N/A
Completed	`NCT05694728` - A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine	Phase 2
Completed	`NCT04391647` - Developing Methods to Investigate Additional Opportunities of HPV Vaccination by Using First-void Urine Samples
Completed	`NCT01446198` - Clinical Evaluation of the APTIMA® HPV Assay Using the PANTHER™ System	N/A
Completed	`NCT01539668` - Hybrid Capture Test on Mobile Unit Program to Improve Cervical Cancer Screening in Brazilian Rural and Remote Areas	Phase 0
Completed	`NCT01567813` - Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)
Completed	`NCT02811367` - The HPV Self-test as a Test of Cure in Madagascar	N/A
Completed	`NCT02067507` - Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County	N/A
Recruiting	`NCT01387997` - e- Ab Sensor-based Real-time Detection of Oncogenic Human Papilloma Viruses	N/A
Completed	`NCT02634190` - Clinical Evaluation of the APTIMA® HPV Assay and Comparison With the HR HC2® Test Using LBC ThinPrep® Specimens
Completed	`NCT00054041` - Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia	Phase 2
Active, not recruiting	`NCT01898494` - Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer	Phase 2